tamoxifen

P2, N=96, Not yet recruiting, University Health Network, Toronto | Initiation date: Apr 2026 --> Jul 2026

P3, N=1556, Suspended, Alliance for Clinical Trials in Oncology | N=1156 --> 1556

PDZK1 functions as a regulator of HER2 stability and may serve as a potential biomarker and therapeutic target in HER2-positive breast cancer. Pharmacological upregulation of PDZK1 may represent a promising combinatorial therapeutic strategy for overcoming therapeutic resistance in breast cancer.

In the tamoxifen resistance context, PAK1 inhibition induced activation of the pro-apoptotic protein BAD and triggered apoptosis while proliferation-related kinases were suppressed in the estrogen-deprived model. Our findings position PAK1 as a mediator of resistance to endocrine therapies suggesting that targeting PAK1 may present a novel strategy to overcome endocrine therapy resistance in ER+ breast cancer.

As postoperative adjuvant therapy, she received four cycles of doxorubicin and cyclophosphamide during pregnancy, followed by four cycles of docetaxel after delivery, along with tamoxifen and tegafur-gimeracil-oteracil potassium. She underwent staged risk-reducing salpingo-oophorectomy and CRRM after surgery for left breast cancer. Even in pregnancy-associated breast cancer complicated by HBOC, management should be individualized with careful consideration of safety, and the timing of each intervention should be determined according to the specific clinical circumstances of each patient.

Finally, we showed that combining PPRHs targeting SF3B1 or SRSF1 with Tamoxifen or 4-hydroxytamoxifen reduced MCF-7 cell viability in an additive or synergistic manner, respectively. Our results indicate that SF3B1 and SRSF1 participate in the generation of different ERα splicing variants and their inhibition by PPRHs could have therapeutic potential in the treatment of estrogen receptor positive breast tumors.

vulgaris-mediated ZnO NPs significantly potentiate the apoptotic effect of Tamoxifen in MCF-7 cells. This synergistic combination allows for a 96-fold reduction in the Tamoxifen dose to achieve IC 50, highlighting its potential to minimize chemotherapy-related side effects while maintaining high therapeutic efficacy.

The combination of ZnO NPs and L. lactis lysate exhibits synergistic pro-apoptotic and cell-cycle inhibitory effects on MCF-7 cells, comparable to tamoxifen. These findings support its potential as a promising complementary or alternative therapeutic strategy for breast cancer.

Meaningful overall survival benefit in hormone receptor-positive, HER2-negative breast cancer from adjuvant exemestane and/or OFS compared with tamoxifen alone is limited to high-risk premenopausal subgroups. Tamoxifen-based ET may not result in optimal outcomes in premenopausal high-grade HER2-negative tumours.

Low-dose tamoxifen was associated with a sustained reduction in breast cancer events, with differences by menopausal status and site of event. These findings support endocrine dose de-escalation to improve the benefit-risk profile of preventive therapy in DCIS and high-risk lesions.

Our findings demonstrate that CBD restores TAM sensitivity through CREB-mediated downregulation of ERα signaling in ER-positive breast cancer. This study suggests the potential application of CBD as a novel adjuvant agent to overcome TAM resistance and improve therapeutic outcomes in patients with ER-positive breast cancer.

Furthermore, HSPB1 and SLC7A5 induced paclitaxel and tamoxifen resistance. Therefore, the HSPB1-SLC7A5 axis contributes to the acquisition of tolerance to both tamoxifen and paclitaxel in breast cancer cells, uncovering a novel therapeutic target against drug resistance in breast cancer.